Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer

Abstract Background The combination of conventional chemotherapy and immune checkpoint inhibitors (ICIs) has been unsuccessful for pancreatic ductal adenocarcinoma (PDAC). Administration of maximum tolerated dose of chemotherapy drugs may have immunosuppressive effects. Methods We thus tested, by us...

Full description

Saved in:
Bibliographic Details
Main Authors: Nan Niu, Keyu Li, Junke Wang, Vanessa Funes, Birginia Espinoza, Pan Li, Jianxin Wang, Melissa Lyman, Mengni He, Brian Herbst, Michael Wichroski, Ruslan Novosiadly, Sami Shoucair, Yiping Mou, Lei Zheng
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Biomarker Research
Subjects:
Pancreatic ductal adenocarcinoma
STING agonist
NLRP3 agonist
Innate immune agonists
Immune checkpoint inhibitors
Chemotherapy
Online Access:https://doi.org/10.1186/s40364-024-00721-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items